History, etiology, prevention, and treatment, second edition at. Bionj is commonly precipitated by a tooth extraction in patients treated with long term, potent, high dose intravenous bisphosphonates for the management of. Oncology agents and medicationrelated osteonecrosis of. Osteonecrosis of the jaw is recognised to be associated with both intravenous and oral bisphosphonate use. Nature and frequency of bisphosphonate associated osteonecrosis of the jaws in australia. In one unusual case, osteonecrosis of the external auditory canal developed in a patient with myeloma who had received intravenous zoledronic acid and amidronate. Clinicians around the united states had begun to see cases of osteonecrosis of both the maxilla and mandible that were seemingly inexplicable with regard to etiology. A case control study s demircan 1, sc isler 2 1 department of dental prosthetic technology, beykent university vocational school, beykent, istanbul, turkey 2 department of oral surgery, istanbul university faculty of dentistry, beykent, istanbul, turkey. Oral and intravenous bisphosphonateinduced osteonecrosis of the jaws. The following protocols have been developed by the bc cancer agency department of oral oncology. Bisphosphonateinduced osteonecrosis of the jaws onj was first described by marx in the year 2003 1. Bisphosphonateassociated osteonecrosis of the jaws there is growing recognition that bisphosphonates may be associated with a rare adverse event called osteonecrosis of the jaws onj. The disease is characterized by the exposure for over 8 weeks of necrotic bone in the maxillofacial region, after bisphosphonate bp therapy, in the absence of prior maxillary radiotherapy 24.
American association of oral and maxillofacial surgeons position paper on bisphosphonaterelated osteonecrosis. Medicationrelated osteonecrosis of the jaw2014 update. Bisphosphonaterelated osteonecrosis of the jaws bronj was initially recognised and reported in the literature in 2002. The disease is characterized by the exposure for over 8 weeks of necrotic bone in the maxillofacial region, after bisphosphonate bp therapy, in the absence of prior maxillary radiotherapy 2. It has been speculated that the medication, especially longterm i. The present study analyzed the clinical features, predisposing factors, and treatment outcome of 11 patients with oral bisphosphonatesrelated onj. Since it was first identified in 2003, bisphosphonate induced osteonecrosis has come under growing scrutiny by medical and dental specialists alike because it affects cancer patients receiving intravenous bisphosphonate therapy and osteoporosis patients receiving oral bisphosphonate therapy and yet its presentation of exposed bone is limited to the jaws. American association of oral and maxillofacial surgeons aaoms in 2007,3 bisphosphonateinduced osteonecrosis of the jaws bionj may be confused clinically with other conditions, such as osteoradionecrosis and osteomyelitis, owing to similar symptoms and radiographic. With a better understanding of this side effect, reported incidences for bronj in oral bisphosphonate users have increased in time. Osteonecrosis of the jaw is a serious complication associated with oral and intravenous bisphosphonate therapy.
The first cases of bisphosphonate induced osteonecrosis of the maxilla and mandible were documented by marx and stern in 2002 in a textbook entitled oral and maxillofacial pathology. The former is of greater concern with regard to increased risk. Osteonecrosis of the jaws onj, also called antiresorptive agent induced osteonecrosis of the jaw aronj and medicationrelated osteonecrosis of the jaw, is an oral complication in patients receiving bisphosphonate or rankl inhibitor therapy. The risk of developing bisphosphonateassociated osteonecrosis of the jaw appears minimal with oral bisphosphonates compared to intravenous preparations. Ostenonecrosis of the jaws, american association of oral. It was first described in 2003, and hundreds of cases have been reported worldwide. Since it was first identified in 2003, bisphosphonateinduced osteonecrosis has come under growing scrutiny by medical and dental specialists alike because it affects cancer patients receiving intravenous bisphosphonate therapy and osteoporosis patients receiving oral bisphosphonate therapy and yet its presentation of exposed bone is limited to the jaws. In 2003 and 2004, three oral surgeons independently reported to the fda information on 104 cancer patients with bisphosphonateassociated osteonecrosis of the jaw. Osteonecrosis of the jaws in patients treated with. Osteonecrosis of the jaw associated with pamidronate therapy. Hellstein dds, ms clinical professor, university of iowa, iowa city, iowa.
Recently, a peculiar form of osteonecrosis limited to the jaws has been discovered especially with the use of intravenous bisphosphonates. The first cases of bisphosphonateinduced osteonecrosis of the maxilla and mandible were documented by marx and stern in 2002 in a textbook entitled oral and maxillofacial pathology. History, etiology, prevention, and treatment john w. Master degree program in oral surgery and implantology. Fda and interested pharmaceutical companies have been. It has since come under increasing scrutiny especially as it affects not only patients receiving intravenous bisphosphonates for cancerrelated conditions unrelated to radiotherapy but also those on oral preparations for osteoporosis. Bisphosphonate associated osteonecrosis of the jaw. The median between these wide ranges is most likely to be closer to being accurate. Osteonecrosis of the jaw is a poorly understood condition that has recently been associated with the use of potent bisphosphonate treatment.
The disorder affects patients with cancer on bisphosphonate treatment for multiple myeloma or bone metastasis from breast, prostate, or lung cancer. Bisphosphonates and osteonecrosis of the jaws journal of. Oral bisphosphonate associated osteonecrosis of the jaws. Medicationrelated osteonecrosis of the jaw wikipedia. Increasingly, oroantral fistulae have been shown to occur as sequelae of bisphosphonate induced osteonecrosis of the jaw and this case report highlights a patient that presented to our ent department and required. Bisphosphonateassociated osteonecrosis of the jaws. Osteonecrosis of the jaws onj, also called antiresorptive agentinduced osteonecrosis of the jaw aronj and medicationrelated osteonecrosis of the jaw, is an oral complication in patients receiving bisphosphonate or rankl inhibitor therapy. Oral and intravenous bisphosphonateinduced osteonecrosis of. Osteonecrosis of the jaws in patients with a history of receiving bisphosphonate therapy. Expert panel recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaws. History, etiology, prevention, and treatment, second edition robert e. Osteonecrosis of the jaw induced by orally administered.
Oral and intravenous bisphosphonateinduced osteonecrosis. Osteonecrosis of the jaw in patients receiving intravenous. However, there are several adverse effects associated with oral bisphosphonates including the bisphosphonate related osteonecrosis of the jaw bronj. Nature and frequency of bisphosphonateassociated osteonecrosis of the jaws in australia. Publications have estimated a wide incidence range for intravenous bisphosphonateinduced osteonecrosis from as little as 0. Harper and fung1, i wish to comment and raise questions on the recent editorial by kahn2 and article by etminan, et al 3. The first three reported cases of bisphosphonateassociated osteonecrosis of the jaw were spontaneously reported to the fda by an oral surgeon in 2002, with the toxicity being described as a potentially late toxicity of chemotherapy. Medicationrelated osteonecrosis of the jaw mon, mronj is progressive death of the jawbone in a person exposed to a medications known to increase the risk of disease, in the absence of a previous radiation treatment. Bisphosphonate related osteonecrosis of the jaws bronj was initially recognised and reported in the literature in 2002. Oral bisphosphonates are the most commonly prescribed antiresorptive drugs for the treatment of osteoporosis.
Osteonecrosis of the jaw in patients treated with bisphosphonates is a relatively rare but well known complication at maxillofacial units around the world. Endodontic implications of bisphosphonateassociated. History, etiology, prevention, and treatment, second due to covid19, orders may be delayed. Dental care protocols bisphosphonate medications are linked to a risk of osteonecrosis of the jaw. Bisphosphonaterelated osteonecrosis of the jaws rev bras reumatol 2011. Increasingly, oroantral fistulae have been shown to occur as sequelae of bisphosphonateinduced osteonecrosis of the jaw and this case report highlights a patient that presented to our ent department and required. Osteonecrosis of the jaw onj is a severe bone disease osteonecrosis that affects the jaws the maxilla and the mandible. This form of osteonecrosis has been termed bisphosphonate induced osteonecrosis of the jaw bionj. Oroantral fistula from bisphosphonate induced osteonecrosis. Changes in serological bone turnover markers in bisphosphonate induced osteonecrosis of the jaws. Advisory task force on bisphosphonaterelated osteonecrosis of the jaws, american association of oral and maxillofacial surgeons. Medicationrelated osteonecrosis of the jaw in patients.
Bisphosphonateinduced osteonecrosis of the jaws bionj article pdf available in journal of maxillofacial and oral surgery april 2019 with 149 reads how we measure reads. Prospective study of 80 patients with multiple myeloma and other malignancies thacharot boonyapakorn a, ingrid schirmer a, peter a. We present current knowledge of bisphosphonateassociated osteonecrosis, a new oral complication in oncology. Interdisciplinary, implantology, oral surgery, general dentistry titleno 18961 isbn 9780867155105 quintessence publishing, usa. Oral and intravenous bisphosphonate induced osteonecrosis of the jaws history, etiology, prevention, and treatment 2nd edition 2011 book softcover, 160 pages, 211 images colored language. Pdf bisphosphonateinduced osteonecrosis of the jaws bionj. Ruggiero, dmd, md, clinical professor, division of oral and maxillofacial surgery, stony brook school of dental medicine, hofstra north shorelij school of medicine, new york center for orthognathic and maxillo. Bisphosphonate induced osteonecrosis of the jaws is the correct term for this real drug complication that most dental practitioners face. Medicationrelated osteonecrosis of the jaw2014 update special committee on medication related osteonecrosis of the jaws. Lang1,3 1vorarlberg institute for vascular investigation and treatment, feldkirch, austria 2private university of the principality of liechtenstein, triesen, principality of liechtenstein. Oral bisphosphonate related osteonecrosis of the jaw.
Oncology agents and medicationrelated osteonecrosis of the jaw. Bisphosphonateinduced exposed bone osteonecrosis osteopetrosis of the jaws. Osteonecrosis of jaws onj might be old, dating back a century in the form of phossy jaw. The groups of patients most likely to present in primary care with an oral bisphosphonate associated osteonecrosis of the. Oral bisphosphonate induced osteonecrosis is a rare but real entity that is less frequent, less severe, more predictable, and more responsive to treatment than intravenous bisphosphonate induced osteonecrosis.
It may lead to surgical complication in the form of impaired wound healing following oral and maxillofacial surgery. Medicationrelated osteonecrosis of the jaw mronj, which was first described in 2002, is a relatively uncommon but potentially serious side effect of treatment with osteoclast inhibitors, such as intravenous highpotency bisphosphonates and denosumab, which decrease the risk of skeletalrelated events in patients with cancer and metastatic bone disease. Osteonecrosis of the jaws associated with the use of bisphosphonates. Oral and intravenous bisphosphonateinduced osteonecrosis of the jaws history, etiology, prevention, and treatment 2nd edition 2011 book softcover, 160 pages, 211 images colored language. All nitrogencontaining bisphosphonates pose a risk, which is related to the route of administration, the potency of the bisphosphonate, and the duration of use. We present current knowledge of bisphosphonate associated osteonecrosis, a new oral complication in oncology. The purpose of this article is to present data from 30 cases of oral bisphosphonate induced osteonecrosis of the jaws contrasting it to the data we have accumulated in 116 cases of intravenous bisphosphonateinduced. As a rheumatologist who has seen and managed bisphosphonate related osteonecrosis of the jaws fung e, medwatch case reports. The class of drugs known as bisphosphonates is discussed. Osteonecrosis of the jaw an overview sciencedirect topics. Bionj is commonly precipitated by a tooth extraction in patients treated with long term, potent, high dose intravenous bisphosphonates for the management of myeloma, breast or prostate. The care and management of bisphosphonate associated.
Various forms of onj have been described over the last 160 years, and a number of causes have been suggested in the literature. The prevalence appears to be approximately 110% in patients with malignancy treated with very high doses of intravenous bisphosphonates. Oral and intravenous bisphosphonate induced osteonecrosis of. History, etiology, prevention, and treatment, 2nd edition epub format while many clinicians currently recognize that bisphosphonate usage is associated with osteonecrosis of the jaws.
Medicationrelated osteonecrosis of the jaw in patients with. The groups of patients most likely to present in primary care with an. Bisphosphonates and bisphosphonate induced osteonecrosis. Risk factors, recognition, prevention and treatment. Several onj cases of patients using oral bisphosphonates have been reported in the literature. Evidence has emerged that bisphosphonate use in cancer patients is associated with osteonecrosis of the jaw. The nook book ebook of the oral and intravenous bisphosphonateinduced osteonecrosis of the jaws. Faculty of dentistry university of barcelona 2 dds, ms, phd. The duration of the use of bisphosphonates was more than 1 year in 93. Bisphosphonate related osteonecrosis of the jaws rev bras reumatol 2011.
Oral and intravenous bisphosphonate induced osteonecrosis. Bisphosphonate induced osteonecrosis of the jaws onj was first described by marx in the year 2003 1. Endodontic implications of bisphosphonateassociated osteonecrosis of the jaws. Bisphosphonateinduced osteonecrosis of the jaw requires early detection and intervention. Osteonecrosis of the jaw and bisphosphonates putting the. Jaw osteonecrosis in patients receiving oral bisphosphonates. Oral bisphosphonates and the risk for osteonecrosis of the. Endodontic implications of bisphosphonate associated osteonecrosis of the jaws. Care guidelines are based on expert opinion but clinical decisions are left up to practitioners. Bisphosphonate associated osteonecrosis of the jaws there is growing recognition that bisphosphonates may be associated with a rare adverse event called osteonecrosis of the jaws onj. Bisphosphonate induced osteonecrosis of the jaw requires early detection and intervention. Oral and intravenous bisphosphonate induced osteonecrosis of the jaws. Description and history of bisphosphonateinduced osteonecrosis of the jaws 2. Oral bisphosphonates and the risk for osteonecrosis of the jaw.
A musthave for the student and practicing clinician alike. Jul 28, 2007 the actions of the commonly prescribed oral bisphosphonates are discussed. The morning fasting serum cterminal telopeptide bone suppression marker is a. Comprehensive case histories related to both oral and intravenous bisphosphonates provide direct guidance in managing patients spanning the full presentation spectrum. Among cancer patients receiving highdose intravenous bisphosphonates, osteonecrosis of the jaw is dependent on dose and duration of therapy, 17 20 and has an estimated incidence of 1% to 12%.
Its pathogenesis is not well understood and its management is difficult. Risks, prevention, and management of oral bisphosphonateinduced osteonecrosis. Although this complication has also been reported in patients receiving antiresorptive agents for. However osteonecrosis of the jaw has been reported following intravenous bisphosphonate use and rarely in those taking them orally. Jun 28, 2007 osteonecrosis of the jaw onj is a wellknown devastating side effect of bisphosphonate therapy for cancer. Osteonecrosis of the jaw onj is a wellknown devastating side effect of bisphosphonate therapy for cancer. Bate british dental journal volume 212, page 253 2012.
1242 1220 64 1486 1464 1394 770 1556 1478 607 411 1385 16 167 1628 505 893 1166 1416 632 1428 1302 376 606 1508 1212 758 194 1391 548 99 123 304 1398 718